Estimated Enrollment:	24
Study Start Date:	December 2006
Estimated Study Completion Date:	March 2007

Inclusion Criteria:

• Healthy, adult male or non-pregnant females (18-45 years of age).
• Capacity to sign a free informed consent form of participation along with two witnesses.
• Use of adequate contraceptive method from the initiation of the study until three months after sporozoite challenge.
• No plans to travel to malaria endemic areas during the course of the study (a year).
• No plans to travel outside the study area from the 7th day until 31st day after the challenge.
• Reachable by phone during the whole study period.
• Able to participate during the whole study period.

Exclusion Criteria:

• Are less than 18 and over 45 years of age.
• Are female who is pregnant at serum positive -HCG screening, planning to become pregnant or who is nursing.
• Have a Duffy negative phenotype.
• Have a G-6-PD deficiency or any other hemoglobinopathy.
• Current or past infection with any species of malaria as demonstrated by a positive TBS on screening or history of a documented positive blood smear. P. vivax IFAT of 1
• Have a known history of allergy to antimalarial drugs or immediate type hypersensitivity reactions to mosquito bites.
• Clinical or laboratory evidence of significant systemic disease, including hepatic, renal, cardiac, immunologic or hematological disease, HIV positive or have any other known immunodeficiency (including receiving immunosuppressive therapy or a history of splenectomy); infected with hepatitis B or C virus; have a history of autoimmune disease (including inflammatory bowel disease, hemolytic anemia, autoimmune hepatitis, rheumatoid arthritis, lupus, etc.) or connective tissue disease or have any other serious underlying medical condition.
• Clinically significant laboratory abnormalities as determined by the Investigator(s).
• Plan to have surgery between enrollment and the end of the challenge follow-up.
• Previous history of alcoholism or drugs use which interfere with social activities of the volunteer
• Have any other conditions that are determined by at least two concurring investigators that may interfere with the capacity to provide free and willing informed consent.

Fundacion Clinica Valle del Lili

Malaria Sporozoite Challenge Model Plasmodium vivax Human Volunteers

Pyrimethamine Protozoan Infections Sulfadoxine-pyrimethamine Amodiaquine Primaquine Anemia Chloroquine

Malaria Sulfadoxine Fever Folic Acid Chloroquine diphosphate Parasitic Diseases

Anti-Inflammatory Agents Anti-Infective Agents Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Renal Agents Antimalarials Antiparasitic Agents Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Amebicides

Antinematodal Agents Coccidiosis Filaricides Anthelmintics Enzyme Inhibitors Anti-Infective Agents, Urinary Folic Acid Antagonists Pharmacologic Actions Analgesics, Non-Narcotic Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents